Compare IOT & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOT | UTHR |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4B | 21.4B |
| IPO Year | 2021 | 1999 |
| Metric | IOT | UTHR |
|---|---|---|
| Price | $31.98 | $471.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 12 |
| Target Price | $50.42 | ★ $498.83 |
| AVG Volume (30 Days) | ★ 5.8M | 343.2K |
| Earning Date | 03-05-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.08 |
| EPS | N/A | ★ 26.38 |
| Revenue | $1,520,629,000.00 | ★ $3,128,400,000.00 |
| Revenue This Year | $29.12 | $13.64 |
| Revenue Next Year | $20.02 | $5.66 |
| P/E Ratio | ★ N/A | $17.90 |
| Revenue Growth | ★ 28.96 | 13.50 |
| 52 Week Low | $31.25 | $266.98 |
| 52 Week High | $61.90 | $519.99 |
| Indicator | IOT | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 33.83 | 40.80 |
| Support Level | $31.25 | $455.63 |
| Resistance Level | $35.87 | $473.89 |
| Average True Range (ATR) | 1.56 | 12.56 |
| MACD | -0.18 | -3.43 |
| Stochastic Oscillator | 12.06 | 27.86 |
Samsara Inc provides an end-to-end solution for operations. The company's Connected Operations Platform consolidates data from its IoT devices and a growing ecosystem of connected assets and third-party systems, and makes it easy for organizations to access, analyze, and act on data insights using its cloud dashboard, custom alerts and reports, mobile apps, and workflows.. The company derives almost all of its revenue from subscription services. Geographically, it derives a majority of its revenue from the United States. The company's customers ranges from small and medium-sized businesses to state and local governments.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.